Achillion Pharmaceuticals, Inc.  

(Public, NASDAQ:ACHN)   Watch this stock  
Find more results for ACHN
12.87
-0.34 (-2.57%)
Nov 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 12.83 - 13.49
52 week 2.45 - 15.00
Open 13.21
Vol / Avg. 2.40M/6.89M
Mkt cap 1.32B
P/E     -
Div/yield     -
EPS -0.62
Shares 100.25M
Beta 2.37
Inst. own 91%
Dec 3, 2014
Achillion Pharmaceuticals Inc at Piper Jaffray Healthcare Conference - 11:30AM EST - Add to calendar
Dec 1, 2014
Achillion Pharmaceuticals Inc at Deutsche Bank BioFEST - 9:15AM EST - Add to calendar
Nov 4, 2014
Q3 2014 Achillion Pharmaceuticals Inc Earnings Release
Sep 3, 2014
Achillion Pharmaceuticals Inc at FBR & Co Inaugural Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -47.29% -48.33%
Return on average equity -51.18% -52.40%
Employees 61 -
CDP Score - -

Address

300 George Street
NEW HAVEN, CT 06511
United States - Map
+1-203-6247000 (Phone)
+1-203-6247003 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The Company is engaged in the development of antivirals for the treatment of chronic hepatitis C infection (HCV), and the development of antibacterials for the treatment of resistant bacterial infections. The Company focuses on the development of four drug candidates for the treatment of HCV: ACH-1625, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase IIa clinical trial, ACH-2684, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial; ACH-2928, a NS5A inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial, and ACH-3102, a NS5A inhibitor for the treatment of HCV, which is being prepared for investigational new drug (IND), filing and initiation of a phase I clinical trial.

Officers and directors

David I. Scheer Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Milind S. Deshpande Ph.D. President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Mary Kay Kay Fenton CPA Chief Financial Officer, Senior Vice President
Age: 50
Bio & Compensation  - Reuters
Gautam Shah Ph.D. Executive Vice President, Chief Compliance Officer
Age: 57
Bio & Compensation  - Reuters
David Apelian M.D., Ph.D. Executive Vice President, Chief Medical Officer
Age: 48
Bio & Compensation  - Reuters
Joseph Truitt Senior Vice President, Chief Commercial Officer
Age: 49
Bio & Compensation  - Reuters
Michael D. Kishbauch Director
Age: 65
Bio & Compensation  - Reuters
Jason S. Fisherman M.D. Independent Director
Age: 56
Bio & Compensation  - Reuters
Gary E. Frashier Independent Director
Age: 75
Bio & Compensation  - Reuters
Kurt C. Graves Independent Director
Age: 46
Bio & Compensation  - Reuters